Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation
The BOVen regimen of Zanubrutinib, Obinutuzumab and Venetoclax showed impressive results in the TP53+ population, albeit in a small sample size here. This is on NCCN and could be considered the right patient.